Abstract
Clozapine is used in the management of treatment‐resistant schizophrenia. However, its utility is limited by the occurrence of agranulocytosis, neutropenia, and leukopenia in up to 3% of patients, necessitating regular monitoring of hematological laboratory indices. In addition, several cases of self‐limiting eosinophilia have been reported in the literature, with most cases occurring 4 weeks after treatment initiation and rarely exceeding a 35% relative eosinophil count (percentage of white blood cells that are eosinophils).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
